Kailera Therapeutics, Inc.

KLRA Nasdaq SEC CIK 2096997
Follow Kailera Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$95.7M −141.4% vs same quarter last year
EPS, diluted −$0.74
Operating cash flow −$133.7M −350.1% vs same quarter last year
Operating income −$106.3M −165.1% vs same quarter last year
Net income by quarter
−$18M
−$28.9M
−$39.6M
−$78.9M
−$111.3M
−$95.7M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing